Obstetrics, gynecology and reproductive medicine guidelines

Breast diseases

PubMed Free Full Text

Breast cancer treatment: monoclonal antibodies

Canada

• Cancer Care Ontario
  • The role of trastuzumab in adjuvant and neoadjuvant therapy in women with HER2/neu-overexpressing breast cancer [2011]

• National Guideline Clearinghouse
  • The use of bevacizumab in metastatic breast cancer. Cancer Care Ontario [2009]
  • The continued use of trastuzumab beyond disease progression in patients with metastatic breast cancer. Cancer Care Ontario [2009]
  • The role of trastuzumab in adjuvant and neoadjuvant therapy in women with HER2/neu-overexpressing breast cancer: a clinical practice guideline. Program in Evidence-based Care [2006]

Germany

• Breast Care
  • Adopting Guidelines into Clinical Practice: Implementation of Trastuzumab in the Adjuvant Treatment of Breast Cancer in Lower Saxony, Germany, in 2007 [2011]

International

• Cochrane Library
  • Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer

Sweden

• Swedish Council on Technology Assessment in Health Care
  • Trastuzumab (herceptin) for metastasized breast cancer [2001]

United Kingdom

• Centre for Reviews and Dissemination, University of York
  • Deconstructing media coverage of trastuzumab (Herceptin): an analysis of national newspaper coverage [2008]

• Health Technology Assessment
  • Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal [2009]

• National Guideline Clearinghouse
  • Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer. National Institute for Health and Clinical Excellence (NICE) [2012]

• National Institute for Health and Clinical Excellence
  • Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer [2012]
  • Breast cancer - bevacizumab (in combination with a taxane) [2011]
  • Breast cancer (early) - trastuzumab [2006]
  • Breast cancer - trastuzumab [2002]

Articles in journals

• Annals of Oncology
  • Adjuvant trastuzumab in early breast cancer [2006]

• Breast Cancer
  • Vascular endothelial growth factor and bevacitumab in breast cancer [2007]
  • Perspective of trastuzumab treatment [2007]
  • Next generation molecular targeted agents for breast cancer: focus on EGFR and VEGFR pathways [2007]

• Canadian Medical Association Journal
  • Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis [2007]

• Cancer
  • Adjuvant targeted therapy in early breast cancer [2009]

• Current Oncology Reports
  • Bevacizumab in the Treatment of Metastatic Breast Cancer: Friend or Foe? [2012]

• Expert Reviews
  • HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies [2011]
  • Bevacizumab and breast cancer: current therapeutic progress and future perspectives [2009]

• Frontiers in Bioscience
  • Her2 cross talk and therapeutic resistance in breast cancer [2008]

• Journal of Cancer Research and Therapeutics
  • Trastuzumab: Is the new evidence revolutionary? [2006]

• Oncologist
  • Integrating Molecular Mechanisms and Clinical Evidence in the Management of Trastuzumab Resistant or Refractory HER-2+ Metastatic Breast Cancer [2011]
  • Bevacizumab Treatment for Advanced Breast Cancer [2011]
  • Minimizing Cardiotoxicity While Optimizing Treatment Efficacy with Trastuzumab: Review and Expert Recommendations [2009]
  • Beyond Trastuzumab: Small Molecule Tyrosine Kinase Inhibitors in HER-2-Positive Breast Cancer [2009]

{Related topics}

• Guidelines
  • Breast cancer treatment